CDK2 and cancer: In solid tumors, miR-181a has been described to play an important role in cancer progression, i.e., augmented miR-181a expression promotes prostate cancer cell proliferation by down-regulating DAX-1 expression and up-regulating PSA, CDK1, and CDK2 [37].